Healthcare & Life Sciences

January 03 2018
Rainer Herzig Medical information and informed consent

Austria - Preslmayr Attorneys at Law

Providing patients with insufficient medical information may impede their ability to give informed consent to proposed medical treatments and thus may trigger the tort liability of physicians or healthcare institutions. However, a March 2017 Supreme Court decision has reduced the scope of the medical information that must be provided to patients.

Author: Rainer Herzig
Read more
Katie Lee Health Canada publishes final guidance documents on quality requirements for regulatory filings

Canada - Smart & Biggar/Fetherstonhaugh

Health Canada recently published the final version of a number of guidance documents and templates which implement new requirements for new drug submissions and abbreviated new drug submissions. The changes will be implemented by way of a phased-in approach, with the general quality guidance requirements being implemented in January 2018 and the new stability requirements and requirements for commercial and pilot scale batches being implemented in October 2019.

Author: Katie Lee
Read more

Recent updates

Urszula Wojtyra Recent developments in Alexion cases

Canada - Smart & Biggar/Fetherstonhaugh

Author: Urszula Wojtyra
William Sarraille California passes sweeping prescription drug price transparency law and co-pay coupon ban

USA - Sidley Austin LLP

Authors: William Sarraille, Meenakshi Datta, Trevor L Wear
Joanne van Harmelen Draft IP Policy Phase 1 – part two: access to medicines, state 'walk-in' rights and parallel import

South Africa - ENSafrica

Author: Joanne van Harmelen

Upcoming event

2nd Pharma and Biotech IP Summit

February 8 2018 - London

IAM’s second annual Pharma and Biotech IP Summit will once again bring together leading IP experts from across life sciences. Last year’s Brexit vote added further uncertainty to an already precarious life sciences IP market and with the Unified Patent Court now thrown into confusion, the political and legislative landscape is one to navigate with caution. Against this backdrop, attendees will hear the latest IP strategies for thriving at a time when regulatory and legislative changes are significantly impacting business models.

For more details go to: